PALBOLIEVA 125 mg contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor. It inhibits CDK4 and CDK6, causing cell-cycle arrest in the G1 phase, thereby slowing the growth of hormone receptor–positive breast cancer cells.

Palbociclib is used for:

1. HR-positive, HER2-negative advanced or metastatic breast cancer
    – In combination with:
  •  Aromatase inhibitors (e.g., Letrozole) as first-line endocrine therapy
  •  Fulvestrant in patients progressing after prior endocrine therapy

Common side effects:

•  Neutropenia

•  Leukopenia

•  Fatigue

•  Nausea

•  Stomatitis

Other side effects:

•  Mild alopecia

•  Diarrhea

•  Upper respiratory tract infections

Serious side effects:

•  Severe neutropenia

•  Infections

CBC monitoring is essential, especially during the first few cycles.

Standard adult dose:

   •  125 mg once daily for 21 consecutive days, followed by 7 days off
   •  Repeated every 28-day cycle

125 mg is the recommended starting dose.

NOTE: This medicine should be taken only under a doctor’s supervision.